Home
About
Pipeline
Science
Media
Contact
More
Two abstracts of SKB264/sac-TMT (TROP2 ADC) were published at 2024 ASCO Annual Meeting to be held in Chicago from May 31 to June 4.
May 24, 2024
Kelun-Biotech and Ellipses A400 (EP0031) Cleared to Start Ph2 Clinical Development by US FDA
May 6, 2024
KLUS Pharma will attend 2024 BIO International Convention held in San Diego from June 3-6.
May 1, 2024
Kelun-Biotech will present the results from two clinical studies of SKB264/sac-TMT at the 2024 AACR Annual Meeting.
April 5, 2024
KLUS Pharma will attend the annual BIO-Europe Spring conference in Barcelona from March 18-20, 2024.
March 4, 2024
KLUS Pharma will attend the 14th World ADC conference in London from March 12-15, 2024.
KLUS Pharma will attend the AACR Annual Meeting in San Diego, CA from April 5-10, 2024.
Kelun-Biotech presented updated clinical results of SKB264 (MK-2870) in TNBC at 2023 SABCS.
December 7, 2023
A400/EP0031 is granted Orphan Drug designation by FDA for RET-fusion positive cancers
November 27, 2023
Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)
August 10, 2023
Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX
July 11, 2023
CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.
June 19, 2023